Diagnostic Solutions - Luminex: xMAP Pneumo14 Immunity Panel

Diagnostic Solutions is proud to have available the first commercial multiplex assay for the identification of 14 Pneumococcal serotypes. Luminex Biosciences Group [LBG] has released a quantitative multiplex assay based on the proven Luminex® xMAP® technology. The assay is intended to provide quantitative assessment of IgG immunoglobulin following administration of the pneumococcal vaccine. The xMAP® Pneumo14: Pneumoccocal Immunity Panel is FDA approved and now available for use with Luminex IS 2.3 Software.

Features:

Simultaneous measurement of 14 serotypes from one patient in a single well.
Serotypes detected [Danish/American designation]
- 1, 3, 4, 8, 9N/9, 12F/12, 14, 19F/19, 23F/23, 6B/26, 7F/51, 18C/56, 19A/57, 9V/68.
Non-specific binding is inhibited through the inclusion of cell wall polysaccharide and PS-22 to the sample diluent.
Six standards are included to provide a quantitative IgG assay measurement.
Low, medium and high controls are provided for each serotype to verify the run accuracy / validity.
The standard curve covers a broad dynamic range to reduce the number of repeats.
The standards are calibrated to industry standard reference material.
Only a small sample size is required to yield multiple assay results.

Workflow Benefits:

Faster Turnaround Time [TAT] compared to performing multiple in-house serotype-specific ELISA assays.
Multiplexing reduces labour costs and improves efficiency.
A standardised method provides high inter-lab and inter-run reproducibility.
Assay process automated using the BMD CARIS™ automation system#.
- # Not validated by Luminex Corporation.
Broad dynamic range reduces the need to dilute and repeat samples for a demonstrated response between pre- and post vaccine samples.

Kit configurations:

1 plate [96 test] or
10 plate kit option
Standards and Controls provided frozen
All other reagents stored at 2-8º C
Millipore vaccum plates not included in the kit.
- available separately from Diagnostic Solutions.